King's College London

Funding Information: The project was supported by grants from Qassim University (Agreement No. 5389-med-2019-2-2-I). Funding Information: Acknowledgments. The clinical trials were carried out at Qassim University Outpatient Clinics and Diabetes and Endocrinology Center at King Fahd Specialist Hospital in Buraydah. The authors thank the study participants, the research nurses, and the study coordinator for contribution in execution of this study. The authors thank Dr. Nazim Ghouri for his advice and suggestions on preparing the manuscript. The authors gratefully acknowledge Qassim University, represented by the Deanship of Scientific Research, on the financial support for this research under the number 5389-med-2019-2-2-I during the academic year 2019. The authors also thank the Research Unit at Buraydah Diabetes and Endocrinology Center, Buraydah, Saudi Arabia, for assisting and supporting the conduct of this clinical trial. Funding. The project was supported by grants from Qassim University (Agreement No. 5389-med-2019-2-2-I). Duality of Interest. S.H. reports personal fees from Novo Nordisk, outside the submitted work. No other potential conflicts of interest relevant to this article were reported. Author Contributions. M.A. and S.H. contributed to data interpretation, wrote and edited the manuscript, and revised its intellectual and technical content. T.A., M.A., and H.A. reviewed and edited the manuscript. F.M. performed statistical analyses and edited the manuscript. M.A. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Prior Presentation. Parts of this study were presented as an oral presentation at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), Paris, France, 2–5 June 2021. Publisher Copyright: © 2022 by the American Diabetes Association.